Ask AI
ProCE Banner Activity

LEAP-015: Phase III Safety Run-in Data With Pembrolizumab + Lenvatinib + Chemotherapy for Advanced Gastroesophageal Cancer

Conference Coverage
Slideset

Pembrolizumab plus lenvatinib and chemotherapy showed a manageable safety profile and preliminary antitumor activity in patients with advanced gastroesophageal cancers.

Released: January 25, 2023

Expiration: January 24, 2024

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by educational grants from

Bristol Myers Squibb

Incyte Corporation

Merck Sharp & Dohme Corp.

Seagen Inc.